43 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All … liabilities in respect of such sales or out-licensing arrangements. We may be required to pay damages (including, but not limited to, litigation
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
, experience, techniques, data and the results of experimentation and testing;
“Litigation Conditions” has the meaning set forth in Section 8.4 … of any of the following: (a) any pending or threatened litigation, governmental investigation, proceeding or action involving the Product; (b) any
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
, the declaration of a share split, or an offering of additional securities;
Litigation, whether pending or threatened;
A change in senior management
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
17 Oct 23
Current report (foreign)
7:01am
and regulatory developments for UX143 are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward
6-K
EX-99.1
qzbxbgxcod8eu r1he3z
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.2
m5xv6h9apcbhk0v5
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
5nycinhzp98 05nl
1 Oct 21
Current report (foreign)
4:43pm
F-3
EX-1.2
wjsvjd3hsfi sqzuc
5 Aug 21
Shelf registration (foreign)
4:33pm
6-K
EX-1.1
4gox2yb 6p
10 Feb 21
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares
5:23pm
424B5
z3wh6gabqopfeuwz
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B5
8796ixc
9 Feb 21
Prospectus supplement for primary offering
5:24pm
6-K
EX-99.1
hp4ljzk0 oymv
17 Dec 20
Mereo BioPharma and Ultragenyx Announce Collaboration and License
5:16pm
424B5
d2nnh2q0q9dpgf
23 Oct 20
Prospectus supplement for primary offering
4:40pm
F-3
ut0haqms2tjx778
6 Oct 20
Shelf registration (foreign)
4:25pm
F-3
EX-1.2
gmfws 8lshiplu9t4
6 Oct 20
Shelf registration (foreign)
4:25pm